WO2014140432A1 - Method and system for tms dose assessment and seizure detection - Google Patents
Method and system for tms dose assessment and seizure detection Download PDFInfo
- Publication number
- WO2014140432A1 WO2014140432A1 PCT/FI2014/050198 FI2014050198W WO2014140432A1 WO 2014140432 A1 WO2014140432 A1 WO 2014140432A1 FI 2014050198 W FI2014050198 W FI 2014050198W WO 2014140432 A1 WO2014140432 A1 WO 2014140432A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eeg
- tms
- accordance
- stimulation
- signal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000001514 detection method Methods 0.000 title description 3
- 238000011491 transcranial magnetic stimulation Methods 0.000 claims abstract description 156
- 238000012544 monitoring process Methods 0.000 claims abstract description 31
- 238000005259 measurement Methods 0.000 claims abstract description 17
- 238000004891 communication Methods 0.000 claims abstract description 7
- 230000000638 stimulation Effects 0.000 claims description 41
- 239000003990 capacitor Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 206010001497 Agitation Diseases 0.000 claims description 10
- 230000002269 spontaneous effect Effects 0.000 claims description 9
- 230000000763 evoking effect Effects 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims 4
- 230000001447 compensatory effect Effects 0.000 claims 3
- 238000012935 Averaging Methods 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 abstract description 28
- 210000004556 brain Anatomy 0.000 description 11
- 210000003128 head Anatomy 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 230000007177 brain activity Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000002184 metal Substances 0.000 description 3
- 230000003534 oscillatory effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005674 electromagnetic induction Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/377—Electroencephalography [EEG] using evoked responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4094—Diagnosing or monitoring seizure diseases, e.g. epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7246—Details of waveform analysis using correlation, e.g. template matching or determination of similarity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
Definitions
- This invention relates to a method and device for TMS dose assessment and seizure detection.
- Transcranial magnetic stimulation is a technique for stimulating the human brain noninvasively.
- TMS causes depolarization or hyperpolarization in the neurons of the brain.
- TMS uses electromagnetic induction to induce weak electric currents using a rapidly changing magnetic field; this can cause activity in specific or general parts of the brain with minimal discomfort, allowing the functioning and interconnections of the brain to be studied.
- TMS thus uses the principle of inductance to get electrical energy across the scalp and skull without the pain of direct percutaneous electrical stimulation. It involves placing a coil of wire on the scalp and passing a powerful and rapidly changing current through it. This produces a magnetic field which passes unimpeded and relatively painlessly through the tissues of the head. This magnetic field, in turn, induces a much weaker electrical current in the brain. In order to induce enough current to depolarize neurons in the brain, the current passed through the stimulating coil must start and stop or reverse its direction within a few hundred microseconds.
- TMS is currently used in several different forms.
- a first form called single-pulse TMS
- a single pulse of magnetic energy is delivered from the coil to the patient.
- rTMS repetitive TMS
- a train of pulses is delivered over a particular time period, with various frequency patterns.
- the frequency sequences upregulate the cortical excitability and in some diseases (e.g. depression) the use of such patterns is advantageous.
- high frequency patterns carry a risk of elevated seizure risk.
- Safety limits for stimulation intensity and frequency are described in international consensus papers (eg. Rossi et al 2009, Wassermann et al 1996).
- a further known way of monitoring the safety and efficacy of a TMS application is to monitor a patient's EEG before and after a TMS session.
- An electroencephalogram is a record of specific brain wave patterns in a patient. EEG systems permit the recording of the brain wave patterns.
- An EEG system typically includes a plurality of conductive electrodes that are placed on a patient's scalp. These electrodes are typically metal and are connected to a preamplifier that processes the signals detected by the electrodes and provides amplified signals to an EEG machine.
- the EEG machine contains hardware and software that interprets the signals to provide a visual display of the brain wave activity detected by the electrodes. This brain wave activity is typically displayed on a strip chart recorder or computer monitor.
- an EEG involves measuring an evoked response before and after a TMS session, and then measuring the spontaneous EEG or non-magnetically evoked EEG responses after the treatment session.
- applying an EEG measurement after the TMS treatment session could prolong the entire treatment session significantly.
- TMS-compatible EEG systems can generally not accommodate TMS measurements because the high-energy dynamic magnetic fields generated by the TMS device induces undesirable voltages in the EEG leads, thereby making the use of conventional EEG hardware unsuitable for the safe and effective monitoring of TMS therapy.
- preamplifiers used in current EEG systems experience saturation caused by the magnetic field generated by the TMS system.
- the magnetic pulse induces a signal in one or more of the EEG electrodes which causes the EEG preamplifiers to saturate.
- Typical preamplifiers used in EEG systems take a relatively long time to recover after being saturated by a TMS pulse.
- One known way of monitoring EEG during TMS includes amplifiers in the EEG system that use a sample-and-hold circuit to pin the amplifier to a constant level during the TMS pulse. The amplifiers are said to recover within 100 microseconds after the end of the TMS pulse. Although this system appears to allow monitoring of the EEG within a short time after the end of a TMS pulse, additional gating and synchronizing circuitry is necessary to control the operation of the EEG amplifiers with respect to the TMS system. Additional gating and sampling circuitry is undesirable because it requires additional circuitry and because it can be complicated. An additional complication that occurs when a patient's EEG is monitored during TMS occurs because of the use of metal electrodes to sense EEG signals. Large eddy currents induced by the TMS pulse or pulses in the metal electrodes can cause localized heating that may result in burns to a patient's scalp. This presents a safety hazard.
- US 2002/007128 Al discloses yet a further way of monitoring EEG during TMS.
- This prior art document discloses a system and method in which there is synchronisation between the timing of operation of the TMS system and the timing of operation of the EEG system. Instead, this disclosure provides a controlling arrangement that monitors the signals provided by the EEG system during operation of the TMS system and stops operation of the TMS system if the EEG signals are in an undesirable state.
- a TMS device to generate, when in an active state, a plurality of magnetic pulses, which can be applied either as a burst, comprising a plurality of pulses grouped together, or as individual pulses, to the patient's head, in accordance with a TMS treatment protocol;
- control means in communication with the TMS device and the EEG system, the control means being arranged to activate the EEG system during the time periods when the TMS device is not generating pulses, such that the EEG data measurement is continuously applied or interleaved with the magnetic pulses being generated in accordance with the TMS treatment protocol, so as to monitor treatment efficacy and detect potential seizures.
- the TMS device is arranged to generate a signal when it is not in an active state and to send this signal to the control means, with the control means accordingly being arranged to trigger the operation of the EEG system when the TMS device is not active.
- the system comprises storage means to store the measured EEG data.
- the TMS device prior to the TMS device applying the plurality of pulses, sends a preparatory signal to the EEG system, the preparatory signal being used by the control means to trigger a recorder to record the EEG data in the storage means.
- the system comprises a seizure monitoring module to detect or predict a seizure in the patient.
- the seizure monitoring module measures the spectral properties of the spontaneous oscillatory brain activity when the TMS device is not generating pulses, and to compare the resulting measurement result to an expected or desired profile so as to detect or predict a seizure in the patient.
- the seizure monitoring module is in communication with the control means, so that in the event of a seizure being detected or predicted, the control means can stop the operation of the TMS device.
- the seizure monitoring module as with the EEG system, is arranged to be activated during the time periods when the TMS device is not generating pulses.
- the system comprises a dosage monitoring module to enable an operator to adjust the dosage of the pulses provided by the TMS device in a subsequent treatment protocol.
- the TMS device is arranged to apply a plurality of pulses during a wait period, the wait period being defined as the time period between bursts of pulses in accordance with the treatment protocol.
- the plurality of pulses are individual pulses generated at random intervals, with the control means being arranged to deactivate the EEG system during the transmission of these pulses and to then activate the EEG system immediately thereafter to monitor and measure the patient's response.
- the TMS device prior to applying the plurality of individual pulses during the wait period, sends a preparatory signal to the EEG system via the control means to enable the EEG system to activate its protection circuitry.
- the control means is arranged to automatically adjust the profile of the pulses being generated by the TMS device and/or recommend an adjusted profile of pulses to be generated by the TMS device in a subsequent treatment session.
- the TMS device comprises a capacitor, to generate an electric current and thus induce a magnetic field to provide the magnetic pulses, a coil or probe to deliver the magnetic pulses, and high voltage charging circuit to charge the capacitor.
- the TMS device is arranged to generate and send the signal to the control means to indicate when it is not in an active state during a time period when the TMS device is not charging the capacitor.
- the system comprises a navigation system to assist in the position of the TMS device.
- the system comprises a patient-response device (typically embedded in the EEG system) to induce visual, sensory, auditory or other types of stimulation, when the TMS device is not generating pulses, for subsequent measurement.
- a patient-response device typically embedded in the EEG system to induce visual, sensory, auditory or other types of stimulation, when the TMS device is not generating pulses, for subsequent measurement.
- the EEG system comprises an amplifier and protection circuitry designed to accommodate the high voltages and current associated with the TMS device, with the control means being arranged to transmit a preparatory signal to the EEG system, prior to a TMS magnetic pulse, so as to activate the protection circuitry.
- generating a plurality of magnetic pulses which can be applied either as a burst, comprising a plurality of pulses grouped together, or as individual pulses, to the patient's head, in accordance with a TMS treatment protocol; measuring EEG data resulting from the TMS treatment protocol being applied to the patient, wherein the EEG data is measured during the time periods when there are no magnetic pulses being generated, such that the step of measuring EEG data is continuously applied or interleaved with the magnetic pulses being generated in accordance with the TMS treatment protocol, so as to monitor treatment efficacy and detect potential seizures.
- the method comprises generating a signal when no magnetic pulses are being generated, with this signal in turn triggering the measuring of the EEG data.
- the method comprises storing the measured EEG data.
- the method comprises generating a preparatory signal, with this signal in turn triggering the storing of the EEG data.
- the method comprises: measuring the spectral properties of the spontaneous oscillatory brain activity when there are no magnetic pulses being generated; and comparing the resulting measurement to an expected or desired profile so as to detect or predict a seizure in the patient.
- the method comprises stopping the generation of the magnetic pulses in the event of a seizure being detected or predicted.
- the method comprises: applying a plurality of individual pulses at random intervals during a time period when there are no magnetic pulses being generated in accordance with the treatment protocol; and measuring the resulting EEG data, so as to enable an operator to adjust the dosage of the TMS pulses in a subsequent treatment protocol.
- the method comprises: deactivating the measuring of the EEG data during the application of the plurality of individual pulses at random intervals; and measuring the EEG data immediately thereafter to monitor and measure the patient's response.
- the method comprises automatically adjusting the profile of the pulses and/or recommending an adjusted profile of pulses to be generated in a subsequent treatment session.
- the method comprises inducing visual, sensory, auditory or other types of stimulation, when there are no magnetic pulses being generated in accordance with the treatment protocol for subsequent EEG data measurement.
- Figure 1 shows a high level schematic view of a system for monitoring a patient's EEG (electroencephalogram) during TMS (Transcranial Magnetic Stimulation), according to an embodiment of the present invention
- Figure 2 shows a timeframe schematic of a TMS protocol and an adjacent EEG protocol, to detect a seizure in the patient, according to one aspect of the present invention
- FIG. 3 shows a timeframe schematic of a TMS protocol and an adjacent EEG protocol, for dosage monitoring, according to a further aspect of the present invention
- FIG. 4 shows a timeframe schematic of a TMS protocol and an adjacent EEG protocol, for dosage monitoring using intermediate random TMS pulses, according to yet a further aspect of the present invention
- FIG. 5 shows a high level flowchart representing a method of monitoring a patient's EEG (electroencephalogram) during TMS (Transcranial Magnetic Stimulation), according to a further embodiment of the present invention.
- a system 10 for monitoring a patient's EEG (electroencephalogram) during TMS (Transcranial Magnetic Stimulation) is shown.
- the system 10 comprises a TMS device 12 to generate, when in active state, a plurality of magnetic pulses.
- the pulses can be applied either as a burst, comprising a plurality of pulses grouped together, as indicated by arrow 14 in Figures 2 to 4, or as individual pulses, as indicated by arrows 16 in Figure 4, to the patient's head 18 in accordance with a TMS treatment protocol.
- TMS treatment protocols often combine active stimulation (corresponding to arrows 14 in Figures 2 to 4) with long pauses in between (as indicated by arrows 20) in Figures 2 to 4. The duration of these pauses often exceeds the duration of active stimulation, as clearly shown.
- the waiting periods defined by the pauses are to be used for measuring diagnostic data that could be interpreted in real-time and used for guiding the TMS treatment protocol, as will be explained in more detail further below.
- a typical treatment protocol used for depression treatment, using rTMS consists of a burst of 40 pulses (arrow 14 in Figures 2 to 4) delivered at 10Hz, followed by a 26 second waiting period (arrows 20 in Figures 2 to 4), repeated until 3000 pulses have been delivered.
- the system 10 further comprises an EEG system 22 to measure spontaneous EEG data associated with the TMS treatment protocol being applied to the patient.
- the purpose of the EEG system 22, as will be explained in more detail further, is to monitor the patient's brain activity in order to extract diagnostic information during the treatment protocol.
- the system 10 further comprises control means 24 in communication with the TMS device 12 and the EEG system 22.
- the control means 24 comprises a controller 26 to activate the EEG system 22 during the time periods when the TMS device 12 is not generating pulses, as indicated by blocks 28 in Figures 2 to 4.
- the EEG data measurement is thus continuously applied or interleaved with the TMS treatment, so as to monitor treatment efficacy and detect potential seizures.
- the TMS device 12 is arranged to generate, and send to the control means 24, a signal when it is not in an active state (i.e. corresponding to a "no-stimulation" event during a treatment protocol, i.e. arrow 20 in Figures 2 to 4).
- the control means 24 is accordingly arranged to trigger the operation of the EEG system 22 when the TMS device 12 is not active.
- the system 10 may comprise storage means 30 to store the measured EEG data.
- the TMS device 12 prior to the TMS device 12 applying the plurality of pulses, the TMS device 12 sends a preparatory signal to the EEG system 22, the preparatory signal being used by the control means 24 to trigger a recorder 32 to record the EEG data in the storage means 30.
- the system 10 comprises a seizure monitoring module 34 (which may be embodied within the EEG system 22) to detect or predict a seizure in the patient.
- the seizure monitoring module 34 measures the spectral properties, including frequency, burst suppression, and phase-locked oscillations, of the spontaneous oscillatory brain activity when the TMS device 12 is not generating pulses, and to compare the resulting measurement result to an expected or desired profile. In other words, this module 34 matches measured spectral properties to the individual's EEG properties (i.e. the patient's typical pre-seizure activity) so as to determine the effects of the operation of the TMS device 12 on the patient.
- the seizure monitoring module 34 is in communication with the control means 24, so that in the event of a seizure being detected or predicted, the control means 24 can stop the operation of the TMS device 12.
- the EEG system 22 quantifies, and records in the storage means 30, spectral properties of the measured EEG signals, and then compares this quantified dated to a benchmark EEG. Typically, if pre-seizure activity is detected, an operator is notified to decide whether to stop treatment. If seizure activity is detected, the operator is notified to stop treatment.
- the seizure monitoring module 34 as with the EEG system 22, is arranged to be activated during the time periods when the TMS device 12 is not generating pulses, corresponding to blocks 20 in Figures 2 to 4.
- the EEG system 10 comprises an amplifier 36 to amplify bioelectric potentials associated with neuronal activity of the brain, to enable unipolar and bipolar EEG measurements, protection circuitry 38 designed to accommodate the high voltages and current associated with the TMS device, and a control unit 40 to connect and control the components of the EEG system 22.
- the control means 24 may be arranged to transmit a preparatory signal to the EEG system 22, prior to a TMS magnetic pulse being generated, so as to activate the protection circuitry 38, and thereby prevent amplifier saturation.
- the TMS device 12 comprises a capacitor 42, to generate an electric current and thus induce a magnetic field to provide the magnetic pulses, a coil or probe 44 to deliver the magnetic pulses, a high voltage charging circuit 46 to charge the capacitor 42, and a control unit 48.
- the capacitor 42 is charged for a few seconds, with the stored energy then being released into the coil 44 as a single or multiple pulses.
- the TMS device 12 is arranged to generate and send the signal to the control means 24 to indicate when it is not in an active state during a time period when the TMS device 12 is not charging the capacitor 42. This enables the EEG system 22 to operate in an environment that is free of commonly known artefacts.
- the system 10 initiates a treatment sequence, e.g. 10Hz / 4 seconds of continuous stimulation with 26 seconds inter- burst intervals.
- a treatment sequence e.g. 10Hz / 4 seconds of continuous stimulation with 26 seconds inter- burst intervals.
- the EEG system 22 is turned off so as to prevent amplifier saturation.
- EEG monitoring is activated in response to the TMS device 12 sending a "non-stimulation" signal to the EEG system 22, corresponding to the start of the waiting period. If the TMS capacitor 42 needs to be charged, the TMS device 12 sends a preparatory signal to the EEG system 22 to prevent recording during the charging procedure.
- the system 10 comprises a dosage monitoring module 50, typically embodied in the EEG system 22, to enable an operator to adjust the dosage of the pulses provided by the TMS system 12 in a subsequent treatment protocol.
- This dosage monitoring ability may be done in one of two ways, with reference to Figures 3 and 4, respectively.
- the TMS treatment sequence may be applied in a conventional manner, and as described above, namely 1 OHz / 4 seconds of continuous stimulation, with 26 seconds inter-burst intervals to define the waiting period, with a typical treatment comprising 75 such sequences.
- the dosage monitoring module 50 of the EEG system 22 is arranged to facilitate the acquisition of averaged EEG epochs with a reasonable signal-to-noise ratio, and to perform quantitative monitoring (e.g. spectrum, coherence and connectivity).
- the TMS treatment sequence described above may be applied, namely 10Hz / 4 seconds of continuous stimulation, with 26 seconds inter-burst intervals.
- the TMS device 12 is arranged to apply a plurality, e.g. 3 - 7, of individual pulses 16 at random intervals during the waiting period 20.
- the waiting period 20 is defined to be the time period between bursts 14 of pulses in terms of the treatment protocol.
- the control means 24 is arranged to deactivate the EEG system 22 during the transmission of these pulses, as indicated by rectangular blocks 52 in Figures 2 to 4, and to then activate the EEG system 22 immediately thereafter, as indicated by blocks 28, to monitor and measure the patient's response.
- the TMS device 12 sends a preparatory signal to the EEG system 22 via the control means 24 to enable the EEG system 22 to activate its protection circuitry 38.
- the properties of evoked responses are quantified so as to extract measures of local excitability (e.g. amplitude, latency, surface properties etc.) and global connectivity (e.g. inter-hemispheric conduction time, amplitude ratio etc.).
- measures of local excitability e.g. amplitude, latency, surface properties etc.
- global connectivity e.g. inter-hemispheric conduction time, amplitude ratio etc.
- control means 24 is arranged to automatically adjust the profile of the pulses being generated by the TMS device 12 and/or recommend an adjusted profile of pulses to be generated by the TMS device 12 in a subsequent treatment session.
- the system 10 comprises a navigation system to assist in the accurate position of the TMS device (i.e. the positioning of the coil or probe 44).
- the system 10 comprises a patient-response device 54, which is typically embedded in the EEG system 22, to induce visual, sensory, auditory or other types of stimulation. This stimulation is applied when the TMS device 12 is not generating pulses, for subsequent measurement. Again, the results of the patient's responses to the induced stimulation are typically stored in the storage means 30.
- the method comprises the step of generating a plurality of magnetic pulses, as indicated by block 82, which can be applied either as a burst, comprising a plurality of pulses grouped together, or as individual pulses, to the patient's head. This may be done in accordance with a TMS treatment protocol.
- the method 80 further comprises the step of measuring EEG data resulting from the TMS treatment protocol being applied to the patient, as indicated by block 84.
- the EEG data is measured during the time periods when there are no magnetic pulses being generated, such that the step of measuring EEG data is continuously applied or interleaved with the magnetic pulses being generated in accordance with the TMS treatment protocol, so as to monitor treatment efficacy and detect potential seizures.
- the present disclosure thus provides a configuration that enables an artefact free measurement of spontaneous EEG and evoked responses during a TMS treatment protocol organised in stimulation patterns.
- the embedding or interleaving of EEG measurements during TMS treatment enables the personalisation and optimization of the treatment sequence.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015519269A JP2015521517A (en) | 2013-03-15 | 2014-03-17 | Method and system for TMS dose evaluation and seizure detection |
CN201480001325.XA CN104394931A (en) | 2013-03-15 | 2014-03-17 | Method and system for tms dose assessment and seizure detection |
KR1020147034610A KR20150023364A (en) | 2013-03-15 | 2014-03-17 | Method and system for tms dose assessment and seizure detection |
RU2014147238A RU2014147238A (en) | 2013-03-15 | 2014-03-17 | SYSTEM AND METHOD FOR TMS DOSE ASSESSMENT AND DETENTION DETECTION |
EP14716617.7A EP2968966A1 (en) | 2013-03-15 | 2014-03-17 | Method and system for tms dose assessment and seizure detection |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/833,954 US20140276184A1 (en) | 2013-03-15 | 2013-03-15 | Method and system for tms dose assessment and seizure detection |
US13/833,954 | 2013-03-15 | ||
FI20135436A FI125325B (en) | 2013-04-26 | 2013-04-26 | Method and system for evaluating TMS dose and detecting seizure |
FI20135436 | 2013-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014140432A1 true WO2014140432A1 (en) | 2014-09-18 |
Family
ID=51535914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2014/050198 WO2014140432A1 (en) | 2013-03-15 | 2014-03-17 | Method and system for tms dose assessment and seizure detection |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2968966A1 (en) |
JP (1) | JP2015521517A (en) |
KR (1) | KR20150023364A (en) |
CN (1) | CN104394931A (en) |
RU (1) | RU2014147238A (en) |
WO (1) | WO2014140432A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102015114483A1 (en) | 2015-08-31 | 2017-03-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Coil arrangement and system for transcranial magnetic stimulation |
WO2018060878A1 (en) * | 2016-09-27 | 2018-04-05 | Mor Research Applications Ltd. | Eeg microstates for controlling neurological treatment |
WO2018104586A1 (en) * | 2016-12-07 | 2018-06-14 | Bittium Biosignals Oy | Interface unit and method for controlling stimulation system |
WO2019211845A1 (en) * | 2018-05-01 | 2019-11-07 | Brainsway Ltd. | Device and method for real-time closed-loop brain stimulation |
WO2021222124A1 (en) * | 2020-04-27 | 2021-11-04 | Cadence Neuroscience, Inc. | Therapy systems with quantified biomarker targeting, including for epilepsy treatment, and associated systems and methods |
US11400289B2 (en) | 2016-10-25 | 2022-08-02 | Brainsway Ltd. | Apparatus and methods for predicting therapy outcome |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109864750A (en) * | 2019-01-31 | 2019-06-11 | 华南理工大学 | Based on the state of mind assessment and regulating system and its working method stimulated through cranium |
CN114610112A (en) * | 2022-01-25 | 2022-06-10 | 湖南华医电磁医学研究院有限公司 | Magnetic shock therapeutic instrument |
KR20230127894A (en) | 2022-02-25 | 2023-09-01 | 재단법인 아산사회복지재단 | Method and device for creating noninvasive dynamic tractography precision neuroimaging |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020007128A1 (en) | 1998-04-27 | 2002-01-17 | Ives John R. | Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation |
US20070142874A1 (en) * | 2005-01-21 | 2007-06-21 | John Michael S | Multiple-symptom medical treatment with roving-based neurostimulation. |
WO2008070001A2 (en) * | 2006-12-01 | 2008-06-12 | Beth Israel Deaconess Medical Center, Inc. | Transcranial magnetic stimulation (tms) methods and apparatus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2483108A (en) * | 2010-08-27 | 2012-02-29 | Walid Juffali | Monitoring neurological electrical signals to detect the onset of a neurological episode |
ES2869957T3 (en) * | 2011-06-03 | 2021-10-26 | Nexstim Oyj | Procedure to combine anatomical connectivity patterns and navigated brain stimulation |
-
2014
- 2014-03-17 WO PCT/FI2014/050198 patent/WO2014140432A1/en active Application Filing
- 2014-03-17 KR KR1020147034610A patent/KR20150023364A/en not_active Application Discontinuation
- 2014-03-17 EP EP14716617.7A patent/EP2968966A1/en not_active Withdrawn
- 2014-03-17 RU RU2014147238A patent/RU2014147238A/en not_active Application Discontinuation
- 2014-03-17 CN CN201480001325.XA patent/CN104394931A/en active Pending
- 2014-03-17 JP JP2015519269A patent/JP2015521517A/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020007128A1 (en) | 1998-04-27 | 2002-01-17 | Ives John R. | Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation |
US20070142874A1 (en) * | 2005-01-21 | 2007-06-21 | John Michael S | Multiple-symptom medical treatment with roving-based neurostimulation. |
WO2008070001A2 (en) * | 2006-12-01 | 2008-06-12 | Beth Israel Deaconess Medical Center, Inc. | Transcranial magnetic stimulation (tms) methods and apparatus |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102015114483A1 (en) | 2015-08-31 | 2017-03-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Coil arrangement and system for transcranial magnetic stimulation |
US10507335B2 (en) | 2015-08-31 | 2019-12-17 | Eberhard Karls Universitaet Tuebingen Medizinizche Fakultaet Geschwister-Scholl-Platz | Coil arrangement and system for transcranial magnetic stimulation |
WO2018060878A1 (en) * | 2016-09-27 | 2018-04-05 | Mor Research Applications Ltd. | Eeg microstates for controlling neurological treatment |
US11198018B2 (en) | 2016-09-27 | 2021-12-14 | Mor Research Applications Ltd. | EEG microstates for controlling neurological treatment |
US11400289B2 (en) | 2016-10-25 | 2022-08-02 | Brainsway Ltd. | Apparatus and methods for predicting therapy outcome |
WO2018104586A1 (en) * | 2016-12-07 | 2018-06-14 | Bittium Biosignals Oy | Interface unit and method for controlling stimulation system |
WO2019211845A1 (en) * | 2018-05-01 | 2019-11-07 | Brainsway Ltd. | Device and method for real-time closed-loop brain stimulation |
WO2021222124A1 (en) * | 2020-04-27 | 2021-11-04 | Cadence Neuroscience, Inc. | Therapy systems with quantified biomarker targeting, including for epilepsy treatment, and associated systems and methods |
Also Published As
Publication number | Publication date |
---|---|
RU2014147238A (en) | 2016-06-10 |
KR20150023364A (en) | 2015-03-05 |
JP2015521517A (en) | 2015-07-30 |
CN104394931A (en) | 2015-03-04 |
EP2968966A1 (en) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014140432A1 (en) | Method and system for tms dose assessment and seizure detection | |
US20140276184A1 (en) | Method and system for tms dose assessment and seizure detection | |
Lefaucheur | Transcranial magnetic stimulation | |
Miniussi et al. | Transcranial stimulation and cognition | |
Veniero et al. | TMS-EEG co-registration: on TMS-induced artifact | |
Antal et al. | Towards unravelling task‐related modulations of neuroplastic changes induced in the human motor cortex | |
Terney et al. | Increasing human brain excitability by transcranial high-frequency random noise stimulation | |
Moliadze et al. | Close to threshold transcranial electrical stimulation preferentially activates inhibitory networks before switching to excitation with higher intensities | |
Batsikadze et al. | Partially non‐linear stimulation intensity‐dependent effects of direct current stimulation on motor cortex excitability in humans | |
Quartarone et al. | Rapid‐rate paired associative stimulation of the median nerve and motor cortex can produce long‐lasting changes in motor cortical excitability in humans | |
US8121695B2 (en) | Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures | |
Matsunaga et al. | Effect of transcranial DC sensorimotor cortex stimulation on somatosensory evoked potentials in humans | |
US10252056B2 (en) | Method and apparatus for preventing or terminating epileptic seizures | |
Madhavan et al. | Focal and bidirectional modulation of lower limb motor cortex using anodal transcranial direct current stimulation | |
Naro et al. | Can transcranial direct current stimulation be useful in differentiating unresponsive wakefulness syndrome from minimally conscious state patients? | |
Lang et al. | Transcranial direct current stimulation effects on I-wave activity in humans | |
US10300294B2 (en) | Bi-phasic paired pulse transcranial magnetic stimulation | |
Sartucci et al. | Changes in pain perception and pain-related somatosensory evoked potentials in humans produced by exposure to oscillating magnetic fields | |
JP2022051571A (en) | Method of identifying and guiding cortical stimulation sites for application of focal-neuromodulation technique | |
US20180169429A1 (en) | Coil arrangement and system for transcranial magnetic stimulation | |
US20190232061A1 (en) | Systems Methods and Devices for Closed Loop Stimulation To Enhance Stroke Recovery | |
Raux et al. | Facilitatory conditioning of the supplementary motor area in humans enhances the corticophrenic responsiveness to transcranial magnetic stimulation | |
Yoshikawa et al. | Temporal and spatial profiles of evoked activity induced by magnetic stimulation using millimeter-sized coils in the mouse auditory cortex in vivo | |
FI125325B (en) | Method and system for evaluating TMS dose and detecting seizure | |
Jochumsen et al. | Induction of long-term depression-like plasticity by pairings of motor imagination and peripheral electrical stimulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2014716617 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14716617 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014147238 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147034610 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015519269 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |